Innocoll Initiates Dosing in Phase II Diabetic Foot Ulcers Trial
Posted on: Friday, 18 April 2008, 06:00 CDT
Innocoll has started dosing in the second of three planned Phase II clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies, to investigate CollaRx Gentamicin Topical for the treatment and prevention of infected diabetic foot ulcers.
This second Phase II trial will investigate the product as an adjunct to systemic antibiotic therapy for treating moderately infected ulcers, as defined according to Infectious Disease Society of America guidelines. The third Phase II trial, planned to commence later in April, 2008, will investigate the product for the prevention of infection in diabetic foot ulcers.
Michael Myers, Innocoll's president and CEO, said: "Since there are currently no topical antibiotics on the market for infected diabetic foot ulcers, we view this Phase II program as a significant step towards treating and potentially preventing this highly serious and widely prevalent complication of diabetes."
Source: Datamonitor
Related Articles
- Schering-Plough Starts Patient Enrollment in Phase 3 Trial for Acadesine, an Investigational Agent Being Studied for Prevention of Complications From Cardiac Surgery
- Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
- ARIAD Initiates Phase 1 Clinical Trial of Its Investigational Oral Multi-Targeted Kinase Inhibitor, AP24534, in Patients With Hematological Cancers
- New Thermometer Reduces Foot Ulcers in Diabetics
- AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
- Isolagen Initiates Phase III Clinical Program to Investigate Isolagen Therapy(TM) for the Treatment of Acne Scars
- Vaccination and Enrollment Are Discontinued in Phase II Trials of Merck's Investigational HIV Vaccine Candidate
- Xoma Initiates Phase I Diabetes Trial
- The Immune Response Corporation Announces That Phase II Preliminary Data Indicate Investigative HIV Immunotherapy IR103 Enhances Immune Responses in Antiretroviral Naive HIV-Infected Patients
- Recent Study Confirms REGRANEX Gel to Be Effective Treatment of Diabetic Neuropathic Foot Ulcers
 |
 |
User Comments (0)
RSS Feeds